Ceva Phylaxia is today a thriving biotech campus, which combines research, development, production of vaccines and commercial operations on one site. When in 1991, Ceva established its first campus for biological expertise in Budapest, the aim was to continue the tradition of veterinary biology started in 1912 with the formation of "Phylaxia" by Janos Koves.

Inspired by such famous researchers as Aladár Aujeszky, József Marek, Domokos Derzsy and Adorján Bartha, names that are familiar to veterinarians worldwide, Ceva Phylaxia's scientists are continuing a long history of Hungarian veterinary excellence.

Today, Ceva Phylaxia is at the centre of a rich collaborative network including many European and international partners, as well as Ceva's other biological campuses including Ceva Biomune, USA, and the group's bio-molecular vaccine research team in Yokohama, Japan among others.

Following the major success of its innovative, immune complex Gumboro vaccine - Transmune^® IBD, Ceva researchers have demonstrated a complete compatibility with that of their latest Newcastle vector vaccine - Vectormune^® ND making vaccination in the hatchery against these widely spread global diseases much simpler.

As a result, Ceva has named this dual vaccination: the 'Perfect Pair' - another step towards helping its customers in the enormous task of improving production and feeding a future population of nine billion.